Kwong Ava, Chau Wai Wang, Mang Oscar W K, Wong Connie H N, Suen Dacita T K, Leung R, Wong Kerry, Lee Andrea, Shea Catherine, Morse Elliot, Law Stephen C K
Division of Breast Surgery, Department of Surgery, The University of Hong Kong, Hong Kong, Hong Kong,
Ann Surg Oncol. 2014 Apr;21(4):1246-53. doi: 10.1245/s10434-013-3377-8. Epub 2013 Dec 12.
Male breast cancer (MBC) is uncommon. As a result, there is limited availability of studies and reviews and even fewer reports from Asia. This is the largest population-based study to compare Chinese MBC patients with female patients during a 10-year period in Hong Kong, Southern China.
A retrospective review of medical records of 132 male and 8,118 female breast cancer patients between year 1997 and 2006 in Hong Kong was performed. Each MBC patient was matched with three female breast cancer patients for further analysis. Different characteristics, overall, breast-cancer specific, and disease-free survivals (DFS) were compared.
Mean age at diagnosis of male and female patients was 64.5 and 52.7 years respectively. Male patients showed lower histological grade, overall stage, smaller tumor size, and more positive sensitivity in hormone receptors. They were more likely to die of causes other than breast cancer. Matched analysis found that the 5-year overall survival (OS), breast-cancer-specific mortality, and DFS for male and female patients were 78.7, 90.5, 90.5, and 77.9, 86.4, and 81.4 % respectively. Male patients had poorer OS at early overall stage but better breast-cancer-specific mortality rates at any age (p < 0.01). Male patients had a significant risk of dying due to any cause in the presence of distant relapse and had less risk of dying when tumor was ER-positive and HER2-positive.
Chinese male breast cancer patients tend to have poorer OS but better breast-cancer-specific survival compared with their female counterparts.
男性乳腺癌(MBC)并不常见。因此,相关研究和综述有限,来自亚洲的报告更是少之又少。这是一项规模最大的基于人群的研究,旨在比较中国男性乳腺癌患者与中国南方香港地区女性乳腺癌患者在10年期间的情况。
对1997年至2006年香港地区132例男性乳腺癌患者和8118例女性乳腺癌患者的病历进行回顾性分析。每例男性乳腺癌患者与3例女性乳腺癌患者匹配以进行进一步分析。比较了不同的特征、总体生存率、乳腺癌特异性生存率和无病生存率(DFS)。
男性和女性患者的诊断时平均年龄分别为64.5岁和52.7岁。男性患者的组织学分级较低、总体分期较低、肿瘤较小且激素受体敏感性更高。他们死于乳腺癌以外原因的可能性更大。匹配分析发现,男性和女性患者的5年总生存率(OS)、乳腺癌特异性死亡率和DFS分别为78.7%、90.5%、90.5%和77.9%、86.4%和81.4%。男性患者在早期总体分期时OS较差,但在任何年龄的乳腺癌特异性死亡率较好(p<0.01)。男性患者在出现远处转移时有因任何原因死亡的显著风险,而当肿瘤为雌激素受体(ER)阳性和人表皮生长因子受体2(HER2)阳性时死亡风险较低。
与女性乳腺癌患者相比,中国男性乳腺癌患者的OS往往较差,但乳腺癌特异性生存率较好。